Top news from MedWatch this week
News about Novo Nordisk, Genmab, Demant, Cochlear, GN, Argenx, Beta Bionics, Catalent, and new EU drug approvals.
Monday
Beta Bionics granted FDA approval for bionic pancreas
Catalent launches big changes to the executive team
Tuesday
Drugmakers eye USD 23bn biotech Argenx ahead of key data
Novo Nordisk to submit obesity tablet for approval this year
Wednesday
Novo Nordisk enters gene-editing therapy collaboration with US biotech Life Edit Therapeutics
Genmab sees big potential in epcoritamab – expects EU approval this year
Thursday
Cochlear sees no other suitors for Demant’s implants business
Novo Nordisk doesn’t expect home run with new gene-editing therapy collaboration
GN completes DKK 2.7bn capital raise
Friday
Demant proposes partial Oticon Medical divestment to ease competition concerns
